KRAS and in situ carcinoma: In a study involving patients with hepatolithiasis—including three without BilIN, 12 with low-grade dysplasia, 16 with high-grade dysplasia, 10 with carcinoma in situ, and 38 with iCCA—KRAS mutations were detected in 48% of BilIN cases and 31.5% of iCCA cases, while no KRAS mutations were observed in patients without BilIN [138].